ZANVASTRO™ (zilganersen) approved by the FDA as the first and only disease modifying treatment for Alexander disease (AxD) in pediatric and adult patients

Impact · against what's priced in

IONS receives a positive catalyst from the FDA approval of ZANVASTRO, the first disease-modifying treatment for Alexander disease. This creates a new revenue stream and establishes a structural monopoly in an ultra-rare disease market.

IONS+0.80

No priced-in read yet